METRNL

Across TCGA pan-cancer cohorts, METRNL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METRNL data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher METRNL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METRNL expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where METRNL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.216	0.535	<.001	73	view →
LUAD	OS	Median	III,IV	0.325	0.824	.002	37	view →
HNSC	DFS	Quartile	All	0.938	0.664	.009	25	view →
CCRCC	DFS	Median	III,IV	0.257	0.839	.006	16	view →
UCEC	DFS	Median	II,III,IV	0.761	1.000	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METRNL–PDAC (DFS)

Open the PDAC breakdown →